Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for acute aluminum phosphide poisoning
IRCT20220618055207N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Intralipid 10% in Aluminium phosphide poisoning (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Heart rate, Systolic blood pressure and 3 more. Started Apr 2020; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20220618055207N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220618055207N1.